drugset / Trial / NCT00193167
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
Timeline
- Start
- 2004-01
- Primary completion
- 2006-04
- Completion
- 2006-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topotecan | Small molecule | — | — |